- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00001965
Cyclosporine A to Treat Hypertrophic Cardiomyopathy (HCM)
Double Blind Placebo Controlled Study of Cyclosporin A in Patients With Left Ventricular Hypertrophy Caused by Sarcomeric Gene Mutations
This study will examine the effectiveness of the drug cyclosporine in treating hypertrophic cardiomyopathy (HCM), a condition in which the heart muscle thickens. The thickened muscle can impair the heart's pumping action or decrease its blood supply, or both. Various symptoms, such as chest pain, shortness of breath, fatigue, and palpitations, may result. In animal studies, cyclosporine prevented heart muscle from thickening in mice that had been engineered to develop thick hearts.
Patients with HCM 18 to 75 years old are screened for this study under protocol 98-H-0102 and this protocol. Screening tests include blood tests, echocardiogram to measure heart thickness, Holter monitor to record heartbeats, treadmill exercise test, and various imaging tests including a thallium scan, radionuclide angiography, magnetic resonance imaging (MRI), and cardiac catheterization to examine heart function and blood supply.
Patients admitted to the study will be randomly assigned to take either cyclosporine tablets or a placebo (a look-alike tablet with no active ingredient) twice a day for 6 months. During a brief hospital stay at the start of the study, blood samples will be taken to measure cyclosporine levels. After discharge, heart rate and blood pressure will be checked and blood tests done during follow-up visits once a week for 2 weeks and then every two weeks until the end of the 6-month treatment period. At that time, patients will be hospitalized a second time for repeat tests to determine the effects of the drug on the heart condition. They include thallium scan, radionuclide angiogram, MRI, treadmill exercise test, cardiac catheterization, and echocardiogram. An echocardiogram and MRI will be repeated 1 year after the start of the study to evaluate long term effects of the drug, if any.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Maryland
-
Bethesda, Maryland, United States, 20892
- National Heart, Lung and Blood Institute (NHLBI)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Patients of either gender, aged 18-75 years, with HCM caused by sarcomeric gene mutations determined by existing protocols.
LV wall thickness of greater than or equal to 20 mm measured in any LV segment by MRI.
Severe symptoms refractory to medical treatment (New York Heart Association functional class III or IV).
No LV outflow tract obstruction at rest greater than 30 mm Hg as determined by cardiac catheterization.
No coronary artery disease (greater than 50% arterial luminal narrowing of a major epicardial vessel).
No chronic atrial fibrillation.
No bleeding disorder (PTT greater than 35 sec, pro time greater than 14 sec, platelet count less than 154 k/mm(3).
No anemia (Hb less than 12.7 g/dl in males and less than 11.0 g/dl in females).
No renal impairment (serum creatinine greater than 1.3 mg/dl).
No hepatitis B or C; nor unexplained abnormal LFTs.
No inability to estimate LV wall thickness.
No positive urine pregnancy test.
No pregnant or lactating female patients.
No concurrent use of immunosuppressives or steroids.
No diabetes mellitus.
No history of malignancy other than skin tumors (squamous and basal cell) in the last 5 years.
No condition that excludes the patient from undergoing an MRI test.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
Collaborators and Investigators
Publications and helpful links
General Publications
- Spirito P, Maron BJ. Relation between extent of left ventricular hypertrophy and occurrence of sudden cardiac death in hypertrophic cardiomyopathy. J Am Coll Cardiol. 1990 Jun;15(7):1521-6. doi: 10.1016/0735-1097(90)92820-r.
- Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J, Grant SR, Olson EN. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell. 1998 Apr 17;93(2):215-28. doi: 10.1016/s0092-8674(00)81573-1.
- Sussman MA, Lim HW, Gude N, Taigen T, Olson EN, Robbins J, Colbert MC, Gualberto A, Wieczorek DF, Molkentin JD. Prevention of cardiac hypertrophy in mice by calcineurin inhibition. Science. 1998 Sep 11;281(5383):1690-3. doi: 10.1126/science.281.5383.1690.
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Heart Diseases
- Cardiovascular Diseases
- Pathological Conditions, Anatomical
- Aortic Valve Disease
- Heart Valve Diseases
- Aortic Stenosis, Subvalvular
- Aortic Valve Stenosis
- Hypertrophy
- Cardiomyopathies
- Cardiomegaly
- Cardiomyopathy, Hypertrophic
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antirheumatic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Dermatologic Agents
- Antifungal Agents
- Calcineurin Inhibitors
- Cyclosporine
- Cyclosporins
Other Study ID Numbers
- 000034
- 00-H-0034
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiomyopathy, Hypertrophic
-
French Cardiology SocietyCompleted1- Primary (Sarcomeric) Hypertrophic Cardiomyopathy | 2- Obstructive Hypertrophic Cardiomyopathy | 3- Non Obstructive Hypertrophic CardiomyopathyFrance
-
Montreal Heart InstituteCanadian Institutes of Health Research (CIHR)Enrolling by invitationCardiomyopathies | Hypertrophic Cardiomyopathy | Hypertrophic Obstructive Cardiomyopathy | Familial Hypertrophic CardiomyopathyCanada
-
Bristol-Myers SquibbActive, not recruitingHypertrophic Cardiomyopathy | Non-obstructive Hypertrophic Cardiomyopathy | Obstructive Hypertrophic CardiomyopathyDenmark, United States, Belgium, Czechia, France, Germany, Israel, Italy, Netherlands, Poland, Portugal, Spain, United Kingdom
-
University of Sao PauloCompletedNon-obstructive Hypertrophic Cardiomyopathy | Obstructive Hypertrophic CardiomyopathyBrazil
-
Yonsei UniversityCompletedFamilial Hypertrophic CardiomyopathyKorea, Republic of
-
Amsterdam UMC, location VUmcRecruitingHypertrophic Cardiomyopathy | Hypertrophic Cardiomyopathy, ObstructiveNetherlands
-
Guangdong Provincial People's HospitalRecruitingHCM - Hypertrophic CardiomyopathyChina
-
Imbria Pharmaceuticals, Inc.CompletedNon-obstructive Hypertrophic CardiomyopathyUnited States, United Kingdom
-
LianBio LLCActive, not recruitingObstructive Hypertrophic CardiomyopathyChina
-
Hangzhou Valgen Medtech Co., LtdActive, not recruitingObstructive Hypertrophic CardiomyopathyChina
Clinical Trials on Cyclosporine A
-
AllerganCompletedDry Eye SyndromesUnited States
-
Zambon SpAEnrolling by invitationBronchiolitis Obliterans | Bronchiolitis Obliterans Syndrome | Obliterative BronchiolitisFrance, United States, Spain, Israel, Belgium, Denmark, Germany, United Kingdom, Austria
-
Bing HanCompletedPure Red Cell Aplasia, AcquiredChina
-
University Hospital, RouenCompletedKidney Transplantation | Primary Prevention | Kidney Failure
-
University of Oslo School of PharmacyCompletedHeart Transplantation | Acute Renal FailureNorway
-
University of Oslo School of PharmacyCompletedHeart Transplantation | Renal TransplantationNorway
-
LEO PharmaWithdrawnAtopic DermatitisNetherlands
-
St. Franziskus HospitalCompletedUveitis | Juvenile Idiopathic ArthritisGermany
-
Sirion Therapeutics, Inc.CompletedDry Eye SyndromesUnited States
-
Tampere University HospitalCompletedUlcerative Colitis Acute